Austar Lifesciences (6118) Stock Overview

Austar Lifesciences Limited, an investment holding company, engages in the provision of integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. It operates through six segments: Liquid and Bioprocess System; Clean Room and Automation Control and Monitoring System; Powder and Solid System; GMP Compliance Service; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment. The company offers liquid and bioprocess systems, including pharmaceutical water, and liquid preparation and bioprocess systems; clean room enclosure, automation control and monitoring systems; and freeze-dryer, sterile filling, and visual inspection equipment, as well as clean utility, powder, and solid equipment and systems. It also provides pharmaceutical process contamination control products; packaging and aseptic containment products; biosafety and lab animal equipment and consumables; laboratory one-stop solutions; and single-use bioprocess equipment and consumables. In addition, the company offers pharmaceutical engineering design, consulting, process technology, facility operations and maintenance, laboratory and digitalization construction, quality risk control, and research and development services. Further, it is involved in the agency and distribution of pharmaceutical equipment, as well as provides contract execution, assembly and pre-assembly, and GMP compliance services. The company was founded in 1991 and is headquartered in Shanghai, China.